Safety, Tolerability and PK Study of AK0529 in Healthy Human

NCT ID: NCT02297594

Last Updated: 2015-10-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2015-06-30

Brief Summary

The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects

Detailed Description

This is a Phase 1, first-in-man, single-center, randomized, double blind, placebo controlled single and multiple ascending dose study in healthy male and female volunteers.

Conditions

Respiratory Syncytial Virus Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AK0529

Generic name: AK0529 Dosage Form: capsule

Group Type: EXPERIMENTAL

AK0529

Intervention Type: DRUG

AK0529 capsule for oral administration

Placebo

Sugar placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Sugar placebo capsule for oral administration

Interventions

AK0529

AK0529 capsule for oral administration

Intervention Type: DRUG

Placebo

Sugar placebo capsule for oral administration

Intervention Type: DRUG

Other Intervention Names

AK0529 capsule; Sugar placebo capsule

Eligibility Criteria

Inclusion Criteria

1. Must be healthy males, or healthy females of non-childbearing potential or surgically sterilized or post-menopausal (amenorrhea for at least 1 year and confirmed by a follicle stimulating hormone [FSH] result of > 20 IU/mL).

2. Must be aged 18 to 55 years of age inclusive.

3. Must have body mass index (BMI) of 18.0 to 31.0 kg/m2 inclusive.

4. Must have total body weight ≥50 kg at screening but ≤100 Kg.

5. Must be willing and able to communicate and participate in the whole study.

6. Must provide written informed consent.

7. Must agree to use an adequate method of contraception (as defined in Section 4.2.1).

8. Must have AST, ALT, total bilirubin, urea, creatinine and hemoglobin within the laboratory reference range at screening and Day -1.

9. Must have QTcF <450 ms, QTcB <450 ms and PR interval <210 ms for screening, Day -1 and pre-dose ECG measurements, and not have any degree of heart block or conduction abnormality.

10. Must have serology demonstrating they are free from infection with hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 and HIV-2)

Exclusion Criteria

1. Male subjects who have currently pregnant partners or who have partners planning to become pregnant during the duration of the study.

2. Evidence or history of clinical significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, hematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection.

3. Clinically relevant (as decided by the investigator and the medical monitor) abnormalities in the ECG (12 standard leads) including any degree of heart block, including asymptomatic bundle branch block.

4. Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.

5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.

6. Electrolyte disturbances, particularly hypokalemia hypocalcemia or hypomagnesemia.

7. Any condition that could possibly affect drug absorption, e.g. gastrectomy or diarrhea.

8. History of post-antibiotic colitis.

9. History of any drug or alcohol abuse in the past 2 years prior to screening.

10. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = 400 mL beer, 25 mL of 40% spirit or a 75 mL glass of wine).

11. Subjects who have a urine cotinine greater than 500 ng/mL at screening will be excluded. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use at least 90 days before screening.

12. Receipt of an investigational drug or participation in another clinical research study within 90 days prior to drug administration.

13. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.

14. Subjects who have previously been enrolled and dosed in this study, except subjects undergoing repeat dosing in Cohort 4F (the fed PK cohort of the SAD part of the study).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Griffin, MD

Role: PRINCIPAL_INVESTIGATOR

Q-Pharm Pty Ltd

Locations

Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus

Brisbane, Queensland, Australia

Countries

Australia

Other Identifiers

AK0529-1001

Identifier Type: -

Identifier Source: org_study_id